Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD. METHODS: CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3. RESULTS: 11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not. CONCLUSION: This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Key biomarkers include polyQ-Htt and Tau, which are detected in the CSF, as well as BDNF, which is measurable in the blood [253,254,255,256].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [255]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unified Huntington's disease rating scale: Reliability and consistency
(1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,079
Differential behavioral effects in frontal lobe disease
Benton, A. L. (1968) · Neuropsychologia · doi:10.1016/0028-3932(68)90038-9 · Cited by 1,431
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Unified Huntington's disease rating scale: reliability and consistency
Kremer, H. P. H. (1996) · Radboud Repository (Radboud University) · Cited by 1,059
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Langbehn, D., Brinkman, R., Falush, D., Paulsen, J., Hayden, M., & on behalf of an International Huntington's Disease Collaborative Group (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00241.x · Cited by 817
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationHuntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
CAG repeat number governs the development rate of pathology in Huntington's disease
Penney, J. B., Vonsattel, J., Macdonald, M. E., Gusella, J. F., & Myers, R. H. (1997) · Annals of Neurology · doi:10.1002/ana.410410521 · Cited by 669
Episodic and Semantic Memory: A Comparison of Amnesic and Demented Patients
Butters, N., Granholm, E., Salmon, D. P., Grant, I., & Wolfe, J. (1987) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688638708410764 · Cited by 595
Rosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
RAN Translation in Huntington Disease
Bañez-Coronel, M., Ayhan, F., Tarabochia, A. D., Zu, T., Perez, B. A., Tusi, S. K., Pletnikova, O., Borchelt, D. R., Ross, C. A., Margolis, R. L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.10.038 · Cited by 354
Elevated neurofilament levels in neurological diseases
Norgren, N., Rosengren, L., & Stigbrand, T. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03219-0 · Cited by 351
Rosas, H. D., Tuch, D. S., Hevelone, N. D., Zaleta, A. K., Vangel, M., Hersch, S. M., & Salat, D. H. (2006) · Movement Disorders · doi:10.1002/mds.20979 · Cited by 346
Wild, E. J., Boggio, R., Langbehn, D., Robertson, N., Haider, S., Miller, J. R. C., Zetterberg, H., Leavitt, B. R., Kuhn, R., Tabrizi, S. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80743 · Cited by 268
Diagnostic criteria for Huntington's disease based on natural history
Reilmann, R., Leavitt, B. R., & Ross, C. A. (2014) · Movement Disorders · doi:10.1002/mds.26011 · Cited by 214
Combination of CSF N -acetylaspartate and neurofilaments in multiple sclerosis
Teunissen, C. E., Iacobaeus, E., Khademi, M., Brundin, L., Norgren, N., Koel-Simmelink, M. J. A., Schepens, M., Bouwman, F., Twaalfhoven, H. A. M., Blom, H. J., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a0fe3f · Cited by 205
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Kuhle, J., Disanto, G., Lorscheider, J., Stites, T., Chen, Y., Dahlke, F., Francis, G., Shrinivasan, A., Radue, E.-W., Giovannoni, G., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001491 · Cited by 175
Huntington disease: A single-gene degenerative disorder of the striatum
Nopoulos, P. C. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/pnopoulos · Cited by 161
Vågberg, M., Norgren, N., Dring, A., Lindqvist, T., Birgander, R., Zetterberg, H., & Svenningsson, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135886 · Cited by 141
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
Axelsson, M., Malmeström, C., Gunnarsson, M., Zetterberg, H., Sundström, P., Lycke, J., & Svenningsson, A. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513490544 · Cited by 125
Jonsson, M., Zetterberg, H., Van Straaten, E., Lind, K., Syversen, S., Edman, Å., Blennow, K., Rosengren, L., Pantoni, L., Inzitari, D., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02808.x · Cited by 111
Self-citationUpdate on Huntington's disease: Advances in care and emerging therapeutic options
Zielonka, D., Mielcarek, M., & Landwehrmeyer, G. B. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.12.013 · Cited by 86
Is Huntington's disease a tauopathy?
Gratuze, M., Cisbani, G., Cicchetti, F., & Planel, E. (2016) · Brain · doi:10.1093/brain/aww021 · Cited by 80
Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
Rodrigues, F. B., Byrne, L., McColgan, P., Robertson, N., Tabrizi, S. J., Leavitt, B. R., Zetterberg, H., & Wild, E. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13719 · Cited by 80
Cerebrospinal Fluid Biomarkers for Huntington’s Disease
Byrne, L. M., & Wild, E. J. (2016) · Journal of Huntington's Disease · doi:10.3233/jhd-160196 · Cited by 78
Constantinescu, R., Romer, M., Oakes, D., Rosengren, L., & Kieburtz, K. D. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.05.012 · Cited by 68
Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease
Vinther-Jensen, T., Börnsen, L., Budtz-Jørgensen, E., Ammitzbøll, C., Larsen, I. U., Hjermind, L. E., Sellebjerg, F., & Nielsen, J. E. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000287 · Cited by 64
Increased levels of total tau protein in the cerebrospinal fluid in Huntington’s disease
Constantinescu, R., Romer, M., Zetterberg, H., Rosengren, L., & Kieburtz, K. D. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.06.010 · Cited by 40
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Cicognola, C., Chiasserini, D., Eusebi, P., Andréasson, U., Vanderstichele, H., Zetterberg, H., Parnetti, L., & Blennow, K. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0130-3 · Cited by 27
Self-citationBiomarkers for Huntington's disease: an update
Scahill, R. I., Wild, E. J., & Tabrizi, S. J. (2012) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2012.701205 · Cited by 11
Cited by
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationHuntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364
Self-citationNeurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 290
“Furthermore, in Huntington disease (HD), CSF NfL fragment levels correlate more strongly with disease progression than do CSF tau levels (Niemela et al., 2017).”
BackgroundByrne, L. M., Rodrigues, F. B., Johnson, E. B., Wijeratne, P. A., De Vita, E., Alexander, D. C., Palermo, G., Czech, C., Schobel, S., Scahill, R. I., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7108 · Cited by 194
Metadata
- Authors
- Niemelä, V., Landtblom, A.-M., Blennow, K., & Sundblom, J.
- Affiliations
- Uppsala University (SE)
- University of Gothenburg (SE)
- Corresponding author
- Niemelä, Valter
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-02-27
- Volume
- 12
- Issue
- 2
- Pages
- e0172762
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5328385
- OpenAlex
- W2592956615
- Cited by
- 63
- References
- 31
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 1
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Åland Cultural Foundation
- The Selander Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Huntington's disease, neurofilament light chain, total tau, cerebrospinal fluid biomarkers, premanifest Huntington's disease, disease stage, disease progression, Unified Huntington's Disease Rating Scale, disease-modifying therapy
- MeSH terms
- Adult, Aged, Axons, Enzyme-Linked Immunosorbent Assay, Female, Humans, Huntington Disease, Male, Middle Aged, Mutation, Cohort Studies, Biomarkers, tau Proteins, Neurofilament Proteins, Disease Progression, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.